What dosage though is required to correct deficiencies? Current guidelines suggest vitamin B6 supplementation of 10 mg/day. With recent advances in the haemodialysis process as outlined above however, is this level of supplementation likely to leave some patients with suboptimal levels? The literature generally recommends 10–50 mg/day. Is it possible that the upper end of this range
rather than the lower end is more suitable? These unanswered questions show that further control trials are required. They should include analysis of losses in the dialysate using different membrane technologies with consideration of the length of time patients see more are on dialysis. Collection of updated dietary data is also warranted. These data would assist in determining the optimal level of supplementation required to achieve favourable vitamin B6 status for today’s haemodialysis population. Appendix S1 Exact search strategy for selected databases. “
“Background: Catalase is an intracellular antioxidant enzyme that is mainly located in cellular peroxisomes and in the cytosol. This LDK378 enzyme plays a significant role in the development of tolerance to oxidative stress in the adaptive response of cells and tissues. The aim of the present study was to examine the association between the –262C/T
polymorphism in the catalase gene and delayed graft function (DGF), acute rejection and chronic allograft nephropathy of kidney allografts. Methods: One hundred eighty-seven recipients of first renal transplants were included in the study. The histories of the patients were analysed regarding DGF, acute rejection and chronic allograft nephropathy. The polymorphism –262C/T in the catalase gene was analysed using the polymerase chain reaction – restriction fragment length polymorphism (PCR-RFLP) method. Results: The risk of DGF was significantly lower in
T allele carriers compared with CC homozygotes: odds ratio = 0.34, 95% confidence interval = 0.17–0.67, P = 0.001. There were no statistically significant associations between the studied polymorphism and acute rejection or chronic allograft nephropathy. Conclusion: The results of this study suggest that –262C/T polymorphism in the catalase gene is associated with DGF in kidney allograft Protein kinase N1 recipients. “
“Aim: While the best treatment of nephrosis-inducing idiopathic membranous nephropathy (IMN) is controversial, some trials have suggested positive outcomes following treatment with oral cyclophosphamide used in combination with steroids. However, data on i.v. cyclophosphamide plus steroids in treatment of nephrotic IMN are few. Methods: The charts of every patient diagnosed with membranous nephropathy in the Renal Division of Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, from January 2003 to December 2009 (n = 189) were retrospectively analyzed. Patients with nephrotic IMN (n = 32) were treated with monthly i.v.